Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSX:ATE, OTCQX:ATBPF) announced that its previously announced application for an Initial Order under the Companies' Creditors Arrangement Act (the
BusinesswireApr 9 19:00 ET
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF) today announced that it received verbal notice on the afternoon of March 28, 2024 from the U.S. Food and Drug Administration ("FDA") that otenaproxesul has been placed on
BusinesswireApr 1 07:00 ET
Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
- The American Society of Regional Anesthesia and Pain Medicine is the largest subspecialty medical society in anesthesiology Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company
BusinesswireMar 20 07:00 ET
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
- AAPM is the primary organization for pain medicine physicians in the U.S. Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target
BusinesswireMar 7 07:00 ET
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, today announced that the arbitrator has found in favor of
BusinesswireMar 4 07:00 ET
Antibe Therapeutics Non-GAAP EPS of -C$0.08
Seeking AlphaFeb 14 08:06 ET
Antibe Reports Q3 2024 Interim Financial and Operating Results
- Successful PK/PD study confirms liver safety, sets stage for upgraded Phase II trial launch next month - Phase II trial enhancements include placebo arm, increased sample size and adaptive design - Ended quarter
BusinesswireFeb 14 07:00 ET
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is extending the Early Warrant
BusinesswireFeb 1 07:00 ET
Antibe Announces Early Warrant Exercise Incentive Program
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce an Early
BusinesswireDec 29, 2023 07:00 ET
Stocks in Play: Antibe Therapeutics Inc.
Baystreet.caDec 12, 2023 10:07 ET
Antibe Therapeutics Announces Amendment to Warrant Terms
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF) (the "Company"), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces
BusinesswireDec 12, 2023 07:00 ET
Antibe Therapeutics Reports Q2 Results
Seeking AlphaNov 13, 2023 11:01 ET
Antibe Completes First Clinical Study of Otenaproxesul's New Formulation
- All treatments well tolerated with no adverse safety signals - No elevations in liver enzymes Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide
BusinesswireNov 1, 2023 07:00 ET
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies targeting pain and inflammation, is pleased to announce Health
BusinesswireSep 28, 2023 07:00 ET
Antibe Announces Results of 2023 Annual Meeting
Antibe Therapeutics Inc. (TSX:ATE, OTCQX:ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its
BusinesswireSep 8, 2023 17:00 ET
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
TORONTO, Aug. 21, 2023 /PRNewswire/ - Dan Legault, Chief Executive Officer and Director, Antibe Therapeutics Inc. (TSX: ATE) shares his Company's story in an interview with TMX Group.The View From Th
PR NewswireAug 21, 2023 15:23 ET
Antibe Therapeutics GAAP EPS of -C$0.11
Seeking AlphaAug 14, 2023 14:10 ET
Antibe Reports Q1 2024 Interim Financial and Operating Results
- Otenaproxesul new formulation tablets manufactured for upcoming PK/PD study - PK/PD study results expected next quarter with Phase II initiation in calendar Q1 2024 - Ended quarter with $34.3 million in cash and
BusinesswireAug 14, 2023 07:00 ET
Antibe Therapeutics Inc.'s (TSE:ATE) Path To Profitability
Yahoo FinanceJun 30, 2023 07:03 ET
Antibe Therapeutics GAAP EPS of -$0.37
Seeking AlphaJun 29, 2023 16:08 ET
No Data
No Data